The partial hold comes after Nurix told the agency of its plan to “transition to an improved manufacturing process,” the drugmaker said in a Nov. 1 news release.
The study is testing Nurix’s drug NX-2127 and involves 160 adult participants with relapsed or refractory B-cell malignancies, according to clinicaltrials.gov. Patients already receiving treatment will continue their regimens, but new enrollment is currently paused with the clinical hold.
